Albert Vilella, PhD.

It works great for Oxford @nanoporetech.com workflows, where you want adaptable MolBio workflows boiled down to a series of Opentrons steps. They also use @illumina but there is a more diverse landscape of 6-figure liquid handling instruments for that...

What I like about Opentrons is that it's a very flexible system, with a python SDK that allows you to think out of the box in terms of automation. The @plasmidsaurus.bsky.social folk have used 3D printing as a way of making the modules even more flexible.

Another example of a custom-made 3D-printed 96-well magnet bead purification device, triggered by a "pipette eject" event on the OpenTrons.
Essentially, if the OpenTrons is thought as a flexible pipetter, then @plasmidsaurus.bsky.social turn pipette events into other MolBio tasks.

Another interesting use of 3D printed plastic adapters, in this case to turn the OpenTrons bays into racks of Oxford @nanoporetech.com PromethION flowcells.

I saw a Youtube video by @omgenomics.com profiling the work that @plasmidsaurus.bsky.social has been doing in streamlining sample preparation for their Plasmid sequencing and RNA-seq products.
Interesting to see @OpenTrons instruments *everywhere*, and how they turn operations "pipette triggers".

#bioinformatics #statistics #memes #bluesci

Illumina at JPM26 Illumina presented at JP Morgan Healthcare on the 13th of January 2026, and here are our highlights from the presentation.

Illumina - albertvilella.substack.com/p/illumina-a...
10X Genomics - albertvilella.substack.com/p/10x-genomi...

Guardant Health JPM26 Guardant Health presented at JP Morgan Healthcare 2026, and here we review their slide deck and give our highlights on the presentation.

Here are my #JPM26 highlights on Substack:
Guardant Health - albertvilella.substack.com/p/guardant-h...
Ginkgo Bioworks - albertvilella.substack.com/p/ginkgo-bio...
Recursion Pharma - albertvilella.substack.com/p/recursion-...
Twist Bio - albertvilella.substack.com/p/twist-bio-...

GeneDx at JPM26 Good levels of growth and solid guidance

GeneDx - open.substack.com/pub/albertvi...

Illumina at JPM26 Illumina presented at JP Morgan Healthcare on the 13th of January 2026, and here are our highlights from the presentation.

Illumina - albertvilella.substack.com/p/illumina-a...
10X Genomics - albertvilella.substack.com/p/10x-genomi...

Element Bio at JPM26 And what are we expecting in February from their NovaSeq killer announcement?

Element Bio - albertvilella.substack.com/p/element-bi...
PacBio and Oxford Nanopore - albertvilella.substack.com/p/jpm26-roun...
Bruker and BillionToOne - albertvilella.substack.com/p/jpm26-roun...
Qiagen, Grail and Element Bio - albertvilella.substack.com/p/jpm26-roun...

Guardant Health JPM26 Guardant Health presented at JP Morgan Healthcare 2026, and here we review their slide deck and give our highlights on the presentation.

Here are my #JPM26 highlights on Substack:
Guardant Health - albertvilella.substack.com/p/guardant-h...
Ginkgo Bioworks - albertvilella.substack.com/p/ginkgo-bio...
Recursion Pharma - albertvilella.substack.com/p/recursion-...
Twist Bio - albertvilella.substack.com/p/twist-bio-...

Rhymes with Haystack | Albert | Substack Biotech, Next Generation Sequencing, Single cell and Spatial Biology, Next Generation Proteomics, Synthetic Biology, Small Molecules and Biologics pharma, and related topics. Click to read Rhymes with...

If you want to learn more about MRD and MCED, follow my substack. albertvilella.substack.com

The survey also found that Turn-Around-Time (TAT) and payor coverage are also the most important factors that oncologists care about.

The oncologists still rank MRD as the tool most likely to affect care in the future, followed by MCED.

From Genomeweb:

MRD and MCED are the most promising Cancer Dx Technologies according to an Oncologist Survey by Labcorp

The survey of 152 oncologists found that Molecular Residual Disease (MRD) and Multi-Cancer Early Detection (MCED) are the most promising tools for oncologists.

10X Genomics at JPM26 A historical perspective of 10X Genomics: and the clash between NGS and Multiomics

10X Genomics at #JPM26
@10xgenomics.bsky.social albertvilella.substack.com/p/10x-genomi...

Illumina at JPM26 Illumina presented at JP Morgan Healthcare on the 13th of January 2026, and here are our highlights from the presentation.

Illumina at #JPM26 open.substack.com/pub/albertvi...

#JPM26

Rhymes with Haystack | Albert | Substack Biotech, Next Generation Sequencing, Single cell and Spatial Biology, Next Generation Proteomics, Synthetic Biology, Small Molecules and Biologics pharma, and related topics. Click to read Rhymes with...

To learn more about biotech stocks, subscribe to albertvilella.substack.com

Active equity funds, those that actively invest in stocks not just buying into indexes, have seen a record amount of withdrawals (outflows). People see a crash coming and are pulling their money out of the stock market.

Another $3.5 M added by ark invest.

Is Recursion Pharma up for acquisition? [COPY] JPM25: Recursion $RXRX Below is the piece I wrote a year ago for JPM Healthcare on Recursion Pharma.

Is Recursion Pharma up for acquisition? [COPY] JPM25: Recursion $RXRX open.substack.com/pub/albertvi...

This is the biggest increase in position from ARKK into Recursion Pharma ever $RXRX

Ark Invest buys a few million dollars worth of Recursive Pharma $RXRX

.@andrew.diffuse.one on 2025 state of LLMs